IM-1617 is a potential first-in-class solid tumor antibody-drug conjugate (ADC) that incorporates HC74, Immunome’s proprietary topoisomerase I (TOP1) inhibitor payload Immunome ADC...
Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on June 1, 2026, the Compensation...
Varegacestat treatment resulted in statistically significant improvements in primary and all key secondary efficacy endpoints Varegacestat demonstrated statistically significant improvement...
Immunome , Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that members of Immunome’s...
New Drug Application (NDA) submitted to the U.S. Food and Drug Administration (FDA) in April 2026 seeking approval of varegacestat for the treatment of adults with desmoid tumors Detailed...
Barchart Research What to Expect from IMNM Earnings IMNM Generated May 8, 2026 Current Price $22.44 EPS Estimate $$-0.60 Consensus Rating Strong Buy Average Move 3.95% Can Immunome's Varegacestat Data...
Barchart Research What to Expect from IMNM Earnings IMNM Generated May 8, 2026 Current Price $22.44 EPS Estimate $$-0.60 Consensus Rating Strong Buy Average Move 3.95% Can Immunome's Varegacestat Data...
Barchart Research What to Expect from IMNM Earnings IMNM Generated May 8, 2026 Current Price $22.44 EPS Estimate $$-0.60 Consensus Rating Strong Buy Average Move 3.95% Can Immunome's Varegacestat Data...
Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on May 1, 2026, the Compensation...
New Drug Application (NDA) supported by positive Phase 3 RINGSIDE results, including significant improvement in progression-free survival vs. placebo (hazard ratio = 0.16, p